Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Rating) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 187,000 shares, a growth of 32.8% from the December 31st total of 140,800 shares. Approximately 0.5% of the shares of the company are short sold. Based on an average trading volume of 73,900 shares, the short-interest ratio is presently 2.5 days.

Hedge Funds Weigh In On Alpha Tau Medical

Hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new position in shares of Alpha Tau Medical during the 2nd quarter valued at approximately $697,000. Ergoteles LLC purchased a new stake in Alpha Tau Medical during the 1st quarter worth about $146,000. Renaissance Technologies LLC purchased a new position in Alpha Tau Medical during the 3rd quarter worth approximately $111,000. Penserra Capital Management LLC acquired a new stake in shares of Alpha Tau Medical in the 1st quarter valued at approximately $40,000. Finally, Tower Research Capital LLC TRC purchased a new position in Alpha Tau Medical during the third quarter worth $37,000. Institutional investors own 1.04% of the company's stock.

Wall Street Analyst Weigh In

Separately, Piper Sandler reduced their target price on shares of Alpha Tau Medical from $19.00 to $12.00 and set an "overweight" rating for the company in a research note on Wednesday, November 23rd.

Alpha Tau Medical Stock Performance

Alpha Tau Medical (NASDAQ:DRTS – Get Rating) last released its quarterly earnings results on Tuesday, November 22nd. The company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.06. Analysts anticipate that Alpha Tau Medical will post -0.62 earnings per share for the current year.

Alpha Tau Medical Company Profile

(Get Rating)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

Recommended Stories

• Get a free copy of the StockNews.com research report on Alpha Tau Medical (DRTS)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.